Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
March 08, 2021 07:30 ET
|
Minerva Neurosciences, Inc
Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 Minerva’s royalty interest in seltorexant acquired by...
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
January 19, 2021 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass. and NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire...
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
July 01, 2020 08:00 ET
|
Minerva Neurosciences, Inc
Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexantCorporate...
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
May 04, 2020 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
April 27, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
March 09, 2020 07:30 ET
|
Minerva Neurosciences, Inc
Company confirms timing of expected top-line results from Phase 3 roluperidone trial in Q2 2020 Management to host conference call today at 8:30 a.m. Eastern Time WALTHAM, Mass., March 09, 2020 ...
Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
November 04, 2019 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019
October 28, 2019 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update for Three Clinical Trials
October 01, 2019 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates
August 05, 2019 07:30 ET
|
Minerva Neurosciences, Inc
During the Second Quarter, Minerva announced several important clinical advancements, including positive top line results from two Phase 2b studies of seltorexant (MIN-202) in major depressive...